„Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway”, NJPS, köt. 40, sz. 2, o. 251–262, dec. 2025, doi: 10.54548/.